## COVID-19 Vaccine Coding and Billing Hot Topics



SPECIAL BULLETIN COVID-19 #148: Pfizer-BioNTech and #147: Moderna COVID-19 Vaccine Biling Guidelines

The CDC has released <u>Interim Guidance for Immunization Services During the COVID-19 Pandemic</u>. This guidance is intended to help immunization providers in a variety of clinical and alternative settings with the safe administration of vaccines during the COVID-19 pandemic.

## **Billing Guidelines**

- The ICD-10-CM diagnosis code required for billing is: Z23 Encounter for immunization.
- The maximum reimbursement rate per unit is: N/A.
- The NDC units should be reported as "UN1".
- Claims must have appropriate NDCs that correspond to the vaccine used for administration and corresponding CPT code.
- Claims must contain both administration codes and vaccine codes to pay.
- Vaccine codes should be reported as \$0.00
- Claims for 1st vaccine dose must have been processed in NCT racks prior to processing a claim for 2nd dose.
- Medicaid and NC Health Choice does not allow copays to be charged for COVID-19 immunization or administrations.
- COVID-19 vaccines are exempt from the Vaccines For Children (VFC) program
- TJ modifier should be used for NC Health Choice claims (age 6 through 18 years)
- EP modifier should be used for all non-NC Health Choice (only Medicaid beneficiaries) younger than 21 years of age.
- CG modifier should be used for claims submitted by a pharmacy participating in the immunization program for both the vaccine and administration codes (EXCEPTION CVS/Walgreens pharmacies participating in the long-term care immunization program for beneficiaries residing at the participating long-term care facility).

## **Vaccine Billing Codes**

MODERNA	PFIZER
<b>91301</b> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	<b>91300</b> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use.
NDC #: 80777-0273-10, 80777-0273-99	NDC #: 9267-1000-01, 59267-1000-02, 59267-1000-03
Administration Codes:	Administration Codes:
<b>0011A:</b> Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	<b>0001A:</b> immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose.
<b>0012A:</b> immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	<b>0002A:</b> Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose.